58 results about "Phospholipase" patented technology

Disclosed is a method for reducing the usage amount of edible fat and oil in a bakery product, the method comprising mixing at least one maltose alpha-amylase and edible fat and oil into dough, and baking same to prepare a bakery product. The usage amount of the edible fat and oil in the dough can be reduced by at least 10 wt % compared with not using the enzyme treatment; and the enzyme may also include cellulase and / or phospholipase. The method does not reduce or substantially reduce the quality of the bakery product, and allows same to have a shelf life of at least 4 days. Also involved is baked fat and oil prepared from the above-mentioned enzyme and edible fat and oil.

The invention relates to the technical field of bioengineering, in particular to a preparation process for extracting antihypertensive peptide from euphausia superba. The process comprises the following steps: adding a ferulic acid / arginine double-grafted pullulan compound in a preparation process, and breaking an emulsification interface by utilizing beta-cyclodextrin adsorption and phospholipase A2 cracking to obtain a soluble pretreatment product; meanwhile, short-time round-trip pH pulse is implemented in the incision enzyme hydrolysis process to activate potential enzyme cutting sites, finally, hydrophobic aggregation peptides are removed through weak acid rapid elution, and excision hydrolysis is performed to obtain a target product with the molecular weight of 0.5-3 kDa, so that dynamic induction and antioxidant steady-state dual control of hydrolysis reaction is realized; the generation proportion of short peptides and the ACE inhibition persistence are improved, and the flavor and the storage stability are remarkably improved. The method is controllable in technological process, high in repeatability and suitable for large-scale preparation of the euphausia superba protein functional peptide and development and application of antihypertensive food.

The present disclosure generally relates to a method for foaming and / or stabilizing foam in a milk or milk- based product, wherein a phospholipase is used to promote foam and / or its stabilization by acting on phospholipids and degrading the same and a use of a phospholipase-treated milk or milk-based product for creating milk foam.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention relates to nucleic acid aptamers for lipoprotein-associated phospholipase A2 (Lp-PLA2), wherein the nucleic acid aptamer is at least one of B76-2, B76-4, and B76-5, with sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The Lp-PLA2 aptamers provided by this invention fill a gap in the field of Lp-PLA2 aptamers and exhibit high affinity and specificity. Three aptamers with good affinity and specificity for Lp-PLA2 have been screened and verified. These aptamers can be formulated into molecular probes or used as detection reagents in methods or kits for detecting Lp-PLA2, improving accuracy. They can also be used to develop novel Lp-PLA2 biosensing methods for molecular identification, showing great application potential in the early warning of cardiovascular disease events.

The invention discloses a method for improving yield of anthocyanin extracted by an enzymic method, according to the method, phospholipase is added and used to act on a cell membrane structure, so that the extraction rate of the anthocyanin and the extraction rate of galactoside in the anthocyanin are obviously improved, and the extraction effect of the anthocyanin is greatly improved through a three-stage enzymolysis system. The total enzymolysis extraction time is within 4 h, and compared with 6-7 h of a traditional enzymatic extraction process, the production period is greatly shortened.

The application discloses application of phospholipase in promoting phosphorus removal in water body, and belongs to the technical field of water treatment. The phospholipase is added to a wetland or a constructed wetland system, the phospholipase catalyzes degradation of organic phosphorus into intermediates, and then shortens the time for conversion of the organic phosphorus into absorbable phosphorus, accelerates the conversion of the phosphorus into the absorbable phosphorus, improves the absorption efficiency of plants on the phosphorus, and thus improves the removal efficiency of the wetland or the constructed wetland system on the phosphorus in the water body.

To provide therapies for subjects suffering from NAFLD.SOLUTION: A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of Patatin-Like Phospholipase Domain Containing 3 is used which comprises a sense strand and an antisense strand. The sense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from a specific nucleotide sequence. The antisense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from another specific nucleotide sequence.SELECTED DRAWING: Figure 1

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

The application provides a lipoprotein phospholipase A2 determination kit for latex immunoturbidimetry, which contains reagent R1 and reagent R2; the reagent R1 comprises the following components: buffer, inorganic salt, anti-interference additive, surfactant and Proclin 300; the reagent R2 comprises the following components: buffer, lipoprotein phospholipase A2 antibody coated latex microspheres, stabilizer, surfactant and Proclin 300. The kit is a liquid kit with strong stability, high accuracy, wide linear range and strong anti-HOOK capability.

The invention discloses an application of glycosylated phosphatidylinositol specific phospholipase D1 (GPLD1) as a sperm-egg recognition and / or binding regulation molecule.

The invention relates to the technical field of pharmaceutical preparations, in particular to an EPA phospholipid soft capsule composition and a preparation method thereof.The composition comprises EPA phospholipid and an enteric soft capsule shell, the EPA phospholipid is prepared from EPA ethyl ester and a reaction substrate under the action of immobilized phospholipase, and the enteric soft capsule shell comprises an enteric material, a plasticizer and purified water. According to the EPA phospholipid enteric-coated soft capsule provided by the invention, EPA ethyl ester is phosphatidylated, and EPA phospholipid is prepared into the enteric-coated soft capsule, so that stable retention of a medicine in the stomach can be reduced, accurate dissolution of the medicine in the small intestine is realized, the problems of peculiar smell and degradation caused by release of EPA ethyl ester in the stomach are effectively avoided, and the EPA phospholipid enteric-coated soft capsule has the characteristic of pH-enzyme dual response.

This invention discloses a phospholipase D and its application in the preparation of ω-3 PUFAs-PA, belonging to the field of functional enzyme technology. The amino acid sequence of the phospholipase D is shown in SEQ ID NO. 9. The application of phospholipase D in the preparation of ω-3 PUFAs-PA is also disclosed. This invention also discloses a recombinant engineered bacterium expressing OUC-nPLD. The phospholipase D of this invention—OUC-nPLD—is a recombinant enzyme obtained by functional domain recombination based on the Non-HKD phospholipase D of *Streptomyces aquamarine*, and its PLD hydrolytic activity is 221.73 U / mg. This invention constructs a recombinant engineered bacterium expressing OUC-nPLD. The OUC-nPLD of this invention can be used for the efficient preparation of ω-3 PUFAs-PA, which is of great significance for the large-scale production of ω-3 PUFAs-PA.

The invention provides a high-yield pulp resin obstacle control complex enzyme preparation and a preparation method and application thereof, the high-yield pulp resin obstacle control complex enzyme preparation comprises the following enzyme components in parts by weight: 8-15 parts of lipase, 5-10 parts of esterase, 3-8 parts of phospholipase and 4-9 parts of modified laccase jointly modified by tannic acid and polyethylene glycol; the auxiliary components comprise 12-20 parts of a hydrophilic surfactant, 2-5 parts of a chelating agent, 6-12 parts of a stabilizer and 15-25 parts of deionized water. Wherein the mass ratio of tannic acid to polyethylene glycol in the modified laccase is (2.5-3.5): 1; the hydrophilic surfactant is a mixture composed of fatty alcohol-polyoxyethylene ether sodium sulfate and cocamidopropyl betaine according to the mass ratio of (2-3): 1. The complex enzyme preparation disclosed by the invention not only can treat triglyceride and free fatty acid, but also can degrade phospholipid components which are easy to neglect, and hydrophobic resin components and phenolic substances which are tightly combined with lignin are attacked through modified laccase, so that the treatment efficiency is higher.

The invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and isomers of such compounds, which bind to patatin-like phospholipase domain-containing protein 3 (PNPLA3) mutation PNPLA3I148M, (I) pharmaceutical compositions comprising a compound of Formula (I), or pharmaceutically acceptable salts thereof, and their use in methods for the treatment of diseases associated with PNPLA3I148M.

This invention provides a mutant phospholipase D for the efficient synthesis of phosphatidylserine, its products, and applications. The mutant is based on phospholipase D with the amino acid sequence shown in SEQ ID NO.1, obtained by mutating one or more of five sites at positions 87, 136, 189, 379, and 458 of this amino acid sequence. The amino acid mutation types at these sites include: L87E, M136G, I189R, E379L, and A458Y. This invention provides both a mutant phospholipase D and its applications. This mutant phospholipase D exhibits improved thermostability and catalytic activity, enabling the catalytic preparation of phosphatidylserine series products. The phosphatidylserine series products prepared using this enzyme can effectively alleviate metabolic syndrome induced by antipsychotic drugs.

The application relates to a preparation method of immobilized phospholipase D and a preparation method of phosphatidylserine thereof, and belongs to the technical field of biotechnology.The preparation method of the immobilized phospholipase D comprises the following steps: (1) mixing mesoporous molecular sieve SBA-15 and a sodium acetate buffer solution to obtain a mixed solution; (2) mixing the mixed solution with an enzyme solution, oscillating, centrifuging, taking the precipitate, cleaning and freeze-drying to obtain the immobilized phospholipase D.The application improves the catalytic performance and stability of PLD by fixing PLD through the immobilization technology, realizes the reusability of PLD, and provides technical support for the industrialized production of the immobilized enzyme of PS.The preparation of phosphatidylserine by the immobilized PLD is optimized, and the optimal process condition of the preparation of PS by the immobilized PLD is obtained.The application further discloses a potential molecular mechanism of PS in treating AD, and provides a theoretical basis for the further clinical application of PS.

The invention discloses an application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide in preparation of drugs for treating allergic diseases, and belongs to the technical field of biological medicines. The invention discloses a new pharmaceutical application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide for the first time, and the N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide serving as an anti-allergic antagonist can effectively inhibit phospholipase C activity of stimulated cells and mediated calcium mobilization thereof in vitro. And the effective dose of the desloratadine, which is a positive drug, is lower in vivo to generate a comparable anti-allergic effect with the desloratadine. Meanwhile, in animal models of allergic rhinitis and atopic dermatitis, compared with a positive drug desloratadine, the compound can effectively inhibit the pathological progress of diseases at a lower dosage. Therefore, the compound has a definite effect of inhibiting in-vitro and in-vivo anaphylaxis, and can be effectively applied to the development of drugs for treating allergic diseases.

The application discloses a panax notoginseng phospholipase gene PnPLA1-21 and application thereof. The nucleotide sequence of the PnPLA1-21 gene is shown as SEQ ID NO:1, and the protein encoded by the PnPLA1-21 gene is shown as SEQ ID NO:2. The application clones the gene, constructs an RNAi carrier pHellsgate 2-PnPLA1-21 by using a Gateway technology, transforms the agrobacterium after the PnPLA1-21 gene in panax notoginseng leaves is instantaneously silenced, inoculates fusarium solani, and carries out resistance analysis. The results show that the disease spot area of the panax notoginseng leaves is significantly expanded after the RNAi silencing, is about 2 times of that of a control group, and the expression level of the PnPLA1-21 is positively correlated with the disease resistance. The application proves for the first time that the PnPLA1-21 positively regulates the resistance of panax notoginseng to the root rot pathogenic bacteria, and can be used for cultivating transgenic panax notoginseng plants resistant to the root rot, and provides new gene resources and technical support for panax notoginseng disease resistance breeding.

The invention relates to the field of synthetic phospholipids, and discloses a method for preparing phosphatidyl ethanolamine synthetic phospholipids under catalysis of phospholipase D. The method comprises the following steps: A, completely dissolving PC in an organic solvent to obtain a PC solution; b, adding ethanolamine into the buffer solution, and adjusting the pH value in an ice bath; c, mixing a metal salt solution with phospholipase D to obtain a fermentation enzyme solution, pouring a buffer solution containing ethanolamine, and uniformly mixing to obtain a water phase; d, mixing the PC solution with a water phase to uniformly disperse PC, and carrying out hydrolysis reaction to obtain a PE crude product reaction solution; e, standing for layering to obtain a water layer, extracting the water layer, and concentrating the obtained organic layer to obtain a PE crude product concentrate; f, refining to obtain a PE crude product I; g, performing column chromatography separation and vacuum concentration to obtain a PE crude product II with the purity not lower than 98%; f, drying to obtain a PE finished product. The method is simple in process, good in enzyme specificity, mild in reaction condition, environment-friendly, high in yield and beneficial to large-scale production of enterprises.

The invention discloses application of a MarR family transcriptional regulation factor SCLAV2489 (GeneBank numbering EFG07562.1) or a phospholipase A2 gene SCLAV4219 (GeneBank numbering EFG09293.1) as a target in improving the fermentation yield of clavulanic acid, the MarR family transcriptional regulation factor SCLAV2489 or the phospholipase A2 gene SCLAV4219 in a streptomyces clavuliformis genome is inactivated or knocked out, so that the fermentation yield of clavulanic acid of a mutant strain can be remarkably improved, and the industrial application prospect is achieved.

Phospholipase A2 receptor polypeptides and uses thereof are provided. Polypeptides are described herein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 1-37, SEQ ID NO: 39, SEQ ID NO: 41-47. The polypeptides described herein are used for the treatment, prevention, and / or diagnosis of primary membranous nephropathy.

The invention discloses egg yolk powder with phospholipid enzymolysis synergistic interface steady-state protection and a preparation method of the egg yolk powder, and belongs to the technical field of creation of high-quality egg yolk powder. Carrying out phospholipase A2 controllable enzymolysis pretreatment on the egg yolk liquid under the protection of nitrogen; performing micro-emulsification steady-state construction on the compound colloid of the Arabic gum and the beta-cyclodextrin; and carrying out temperature-controlled spray drying on the pretreatment liquid. The key processes are coupled to form a steady-state pretreatment scheme for actively reconstructing a lipid dispersion state from a molecular level, so that the passive defect that oxidation deterioration cannot be fundamentally inhibited due to the fact that a traditional process only depends on later packaging or external addition of an antioxidant is overcome, and the egg yolk powder with low surface free fat coverage rate (SFCR is less than or equal to 3.5%) is produced. After the product is stored for 90 days in an accelerated manner, the peroxide value growth rate (delta POV) is less than or equal to 60.0%, the key smelly aldehyde total concentration (TCKA) is less than or equal to 2.5 mu g / kg, and the emulsifying activity index retention rate is greater than or equal to 85.0%.

A process for degumming a vegetable oil comprising the steps of: a) providing a vegetable oil containing a quantity of phospholipids, b) contacting the oil with one or more phospholipases in presence of water, c) separating the reaction mixture of step b) into a light phase and a heavy phase, and d) producing a degummed vegetable oil, wherein the phospholipase has at least 75 percent sequence identity to SEQ ID NO: 1, wherein more than 75% or 85% or 90% of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is hydrolyzed, and more than 25% or 35% or 50% of phosphatidic acid (PA) is hydrolyzed and wherein the process is carried out at a temperature of 70°C or above.

This invention belongs to the field of molecular biology technology, specifically disclosing the application of the phospholipase PLA2G7 gene in the preparation of a formulation that enhances the anti-Salmonella activity of avian macrophages. The avian species is chicken. The CDS sequence of the phospholipase PLA2G7 gene is shown in SEQ ID NO:1. By increasing the expression level or activity of the phospholipase PLA2G7 gene in chicken macrophages, the invention promotes the expression of pro-inflammatory factors in chicken macrophages and enhances their phagocytic and bactericidal ability against Salmonella. Compared with existing technologies, this invention demonstrates that increasing the expression level or activity of the phospholipase PLA2G7 gene in chicken macrophages can promote the expression of pro-inflammatory factors in chicken macrophages and enhance their phagocytic and bactericidal ability against Salmonella.

The application discloses corn phosphatidyl phospholipase C4, a coding gene thereof and application of the corn phosphatidyl phospholipase C4 in enhancing disease resistance. The corn phosphatidyl phospholipase C4 can endow transgenic rice with wide resistance without affecting the yield of the rice. The amino acid sequence of the corn phosphatidyl phospholipase C4 is SEQ ID No.2. The sequence of the coding gene is SEQ ID No.1. Research shows that the corn phosphatidyl phospholipase C4 gene is located in the cell membrane, overexpression of the corn phosphatidyl phospholipase C4 gene in rice can improve the resistance of the rice to rice blast caused by Magnaporthe oryzae and rice bacterial leaf blight caused by Xanthomonas oryzae, and meanwhile, the agronomic characters of the rice are evaluated, and it is found that the gene does not affect the ear length, grain length, 1000-grain weight and yield per plant of the rice.

The invention discloses a flavoring agent for branched chain amino acid and a preparation method of the flavoring agent, and belongs to the technical field of food additives. The flavoring agent comprises a flavoring component and a composite lipid carrier coating the core component, wherein the lipid carrier is composed of phospholipid, auxiliary lipid and a structure enhancer. By introducing high-melting-point phytosterol, a soft-hard alternate microscopic phase separation structure is constructed in a flexible phospholipid bimolecular layer, on one hand, the structure provides compact physical barrier by utilizing a rigid framework formed by phytosterol, the oxidation resistance and the humidity resistance of the flavoring component are remarkably improved, and the stability of the shelf life is ensured; and on the other hand, a phospholipid region is reserved as an enzymolysis target, and the carrier is structurally disintegrated within 45 seconds when being in contact with saliva and releases the flavoring component in a pulse manner by utilizing the specific shearing action of oral cavity phospholipase A2.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and / or a PNPLA3-associated disorder.

The invention relates to the technical field of biology, in particular to an antibody specifically binding to PLA2R or an antigen binding fragment thereof, a preparation method and application. The antibody or the antigen binding fragment thereof contains a heavy chain variable region and a light chain variable region, wherein a complementary determining region of the heavy chain variable region has an amino acid sequence consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region as shown in SEQ ID NO.1; the complementarity determining region of the light chain variable region has an amino acid sequence consistent with the amino acid sequences of VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region as shown in SEQ ID NO.2. The antibody or the antigen binding fragment thereof has good specific binding capacity with a phospholipase A2 receptor (PLA2R), and can be used for identifying an antiphospholipase A2 receptor antibody (PLA2RA) or a PLA2R antigen, and performing or assisting in performing diagnosis detection on PLA2RA positive diseases.

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts and isomers of such compounds that bind to patatin-like phospholipase domain-containing protein 3 (PNPLA3) mutant PNPLA3 I148M, (I) pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in methods for treating PNPLA3 I148M-associated diseases.(I)